%0 Journal Article
%T Bisphosphonates and innovative drugs in the prevention of skeletal complications secondary to metastatic prostate cancer
%A Nabil Ismaili
%A Ali Tahri
%A Rhizlane Belbaraka
%J Clinical Cancer Investigation Journal
%@ 2278-0513
%D 2013
%V 2
%N 4
%R 10.4103/2278-0513.121517
%P 294-297
%X Over than 80% of patients with locally advanced prostate cancer will develop bone metastases during the disease management. These metastases are often responsible for complications that impaired the quality of life, impaired the prognosis and increased the mortality by prostate cancer (PC). Two drugs are currently approved by the scientific community in the prevention of skeletal complications secondary to castration-resistant prostate cancer metastatic to bone (CRPCMB), zoledronic acid at a dose of 4 mg intravenously every 3-4 weeks and denosumab at a dose of 120 mg subcutaneously every 4 weeks. This aim of the preset paper was to review the current literature on the mechanism of action, efficacy, and safety profile of these two classes of molecules in the management of CRPCMB.
%U https://ccij-online.org/article/bisphosphonates-and-innovative-drugs-in-the-prevention-of-skeletal-complications-secondary-to-metastatic-prostate-cancer-139